Smarter Cancer Care
In collaboration with thousands of physicians around the world, over one million patients improved their outcomes with the Oncotype IQ portfolio of genomic tests.
Learn More

UroCareLive Webinar

September 23, 2020, 4:30pm ET

Join the live LUGPA Virtual Crossfire Series discussion "Commercial Genomic Assays for Localized Prostate Cancer: How Do They Compare?" featuring Drs. Neal Shore and Andrew Stephenson.

Society of Surgical Oncology 2020 Virtual Event

Now Available On-Demand

Access the SSO 2020 International Conference on Surgical Cancer Care on-demand to view hundreds of oral abstract presentations, videos and posters.

CancerNetwork Webinar

Now Available On-Demand

Join Dr. Timothy Kuzel (Rush University Medical Center) to learn more about how “Biomarkers for Advanced-Stage Prostate Cancer Patients” can help personalize treatment decisions.

ASCO20 Virtual Scientific Program

Exact Sciences Showcases Continued Progress in Cancer Diagnostics

See new data for the Oncotype DX Breast Recurrence Score test and how it changes treatment decisions for patients with early-stage breast cancer.

To everyone on the front lines of patient care during this time,

THANK


YOU.

We are here to support you whenever you need us.

Exact Sciences' Response to COVID-19

We want to assure you that our Oncotype DX tests remain readily available and that our laboratory continues to operate. Our patient-critical work teams continue to operate, following all safety procedures and practices.
Real People.
Real Results.
When Amy was diagnosed with breast cancer, she was scared. Her Oncotype DX Breast DCIS Score result made her feel in control.
Learn More
Healthcare Savings
How much do ineffective cancer treatments cost the healthcare system? In the US alone, Oncotype IQ tests have saved more than $3.5 billion.
Learn More
Practice Tools

The Eighth Edition AJCC Staging Manual is now effect, and it has changed staging for T1-2 N0 M0 breast cancer patients.
Learn How
Latest TAILORx Data
The landmark TAILORx results provide definitive answers on which early stage ER+, HER2-, N0 breast cancer patients can benefit from chemotherapy.
Learn More

Stay in Touch

Have questions? We're here to help.

 Contact Us
Copyright © 2004- Genomic Health, Inc., a wholly owned subsidiary of Exact Sciences Corporation. All Rights Reserved.
In the US and certain other jurisdictions, Genomic Health, Oncotype, Oncotype DX, Oncotype IQ, Breast Recurrence Score, Recurrence Score, DCIS Score, Colon Recurrence Score, Genomic Prostate Score, GPS, AR-V7 Nucleus Detect, Pass It On: Until Every Woman Knows, and Making Cancer Care Smarter are trademarks of Genomic Health, Inc. Exact Sciences is a trademark of Exact Sciences Corporation.
Making cancer care smarter.™
X

We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.